PREVACID (lansoprazole) Delayed-Release Capsules PREVACID (lansoprazole) For Delayed-Release Oral Suspension PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration
ثبت نشده
چکیده
Dual Therapy: PREVACID Amoxicillin 30 mg 1 gram Three times daily for 14 days Benign Gastric Ulcer Short-Term Treatment (1.4) 30 mg Once daily up to 8 wks NSAID-associated Gastric Ulcer (1.6) Healing Risk Reduction 30 mg 15 mg Once daily for 8 wks Once daily up to 12 wks GERD (1.7) Short-Term Treatment of Symptomatic GERD 15 mg Once daily up to 8 wks Short-Term Treatment of EE 30 mg Once daily up to 8 wks Pediatric (8.4) (1 to 11 years of age) Short-Term Treatment of Symptomatic GERD and Short-Term Treatment of EE Page 1 of 21 ≤ 30 kg 15 mg Once daily up to 12 wks > 30 kg 30 mg Once daily up to 12 wks (12 to 17 years of age) Short-Term Treatment of Symptomatic GERD Nonerosive GERD 15 mg Once daily up to 8 wks EE 30 mg Once daily up to 8 wks Maintenance of Healing of EE (1.8) 15 mg Once daily
منابع مشابه
PREVACID (lansoprazole) Delayed-Release Capsules PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration
-----------------------------DRUG INTERACTIONS-------------------------- • Atazanavir: Do not co-administer with atazanavir. (7.1) • Drugs with pH-Dependent Absorption: May interfere with the absorption of drugs where gastric pH is important for bioavailability. (7.1) • Warfarin: Concomitant warfarin use may require monitoring for increases in INR and prothrombin time. (7.2) • Tacrolimus: Conc...
متن کاملLansoprazole is an antituberculous prodrug targeting cytochrome bc1
Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, by testing a panel of FDA-approved drugs in a host cell-based assay, we show that the blockbuster drug lansoprazole (Prevacid), a gastric pro...
متن کاملNew Drugs Drug News
124 P&T® • March 2009 • Vol. 34 No. 3 NEW DRUGS Dexlansoprazole (Kapidex) For Esophageal Disease The FDA has approved dexlansoprazole delayed-released capsules (Kapidex, Takeda Pharmaceuticals) to treat heartburn associated with symptomatic non erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and the maintenance of healed erosive esophagitis. Acid reflux disea...
متن کاملA randomized, crossover pharmacodynamic study of immediate‐release omeprazole/sodium bicarbonate and delayed‐release lansoprazole in healthy adult volunteers
Proton pump inhibitors (PPIs) effectively block gastric acid secretion and are the treatment of choice for heartburn. PPIs differ, however, in onset of action and bioavailability. In this single-center, open-label, three-way crossover study, onset of action of immediate-release omeprazole 20 mg/sodium bicarbonate 1100 mg (IR-OME) and delayed-release (DR) lansoprazole 15 mg was evaluated in 63 h...
متن کاملIngestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
Objectives. We evaluated the ingestibility and formulation quality of one branded (formulation A) and five generic (formulations B, C, D, E, and F) lansoprazole orally disintegrating (OD) tablets. Methods. Ingestibility, including the oral disintegrating time, taste, mouth feeling, and palatability, was examined by sensory testing in healthy subjects. Formulation qualities, including salivary s...
متن کامل